430 related articles for article (PubMed ID: 17397875)
41. [Effects of polydatin on bleomycin-induced pulmonary fibrosis in rats].
Zhang Y; Chen L; Liang B
Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(24):3528-34. PubMed ID: 22368872
[TBL] [Abstract][Full Text] [Related]
42. A further investigation concerning correlation between anti-fibrotic effect of liposomal quercetin and inflammatory cytokines in pulmonary fibrosis.
Baowen Q; Yulin Z; Xin W; Wenjing X; Hao Z; Zhizhi C; Xingmei D; Xia Z; Yuquan W; Lijuan C
Eur J Pharmacol; 2010 Sep; 642(1-3):134-9. PubMed ID: 20510684
[TBL] [Abstract][Full Text] [Related]
43. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta.
Kalayarasan S; Sriram N; Sudhandiran G
Life Sci; 2008 Jun; 82(23-24):1142-53. PubMed ID: 18462759
[TBL] [Abstract][Full Text] [Related]
44. Leukotriene C4 aggravates bleomycin-induced pulmonary fibrosis in mice.
Hirata H; Arima M; Fukushima Y; Sugiyama K; Tokuhisa T; Fukuda T
Respirology; 2013 May; 18(4):674-81. PubMed ID: 23432979
[TBL] [Abstract][Full Text] [Related]
45. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
[TBL] [Abstract][Full Text] [Related]
46. Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice.
Gou S; Zhu T; Wang W; Xiao M; Wang XC; Chen ZH
Int Immunopharmacol; 2014 Oct; 22(2):498-504. PubMed ID: 25111852
[TBL] [Abstract][Full Text] [Related]
47. Feitai, a Chinese herbal medicine, reduces transforming growth factor-beta1 and monocyte chemoattractant protein-1 expression in bleomycin-induced lung fibrosis in mice.
Shen Y; Zhao HL; Du J; Li YT; Tan F; Huang CG; Pei G
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1071-7. PubMed ID: 16445573
[TBL] [Abstract][Full Text] [Related]
48. Significance of thrombin in bleomycin-induced pulmonary fibrosis.
Tani K; Yasuoka S; Ogura T
Tokushima J Exp Med; 1990 Jun; 37(1-2):39-48. PubMed ID: 1701928
[TBL] [Abstract][Full Text] [Related]
49. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse.
Yasui H; Gabazza EC; Tamaki S; Kobayashi T; Hataji O; Yuda H; Shimizu S; Suzuki K; Adachi Y; Taguchi O
Am J Respir Crit Care Med; 2001 Jun; 163(7):1660-8. PubMed ID: 11401891
[TBL] [Abstract][Full Text] [Related]
50. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis.
Manoury B; Nenan S; Leclerc O; Guenon I; Boichot E; Planquois JM; Bertrand CP; Lagente V
Respir Res; 2005 Jan; 6(1):11. PubMed ID: 15663794
[TBL] [Abstract][Full Text] [Related]
51. Effects of Th2 pulmonary inflammation in mice with bleomycin-induced pulmonary fibrosis.
Hirata H; Arima M; Fukushima Y; Ishii Y; Tokuhisa T; Fukuda T
Respirology; 2008 Nov; 13(6):788-98. PubMed ID: 18811877
[TBL] [Abstract][Full Text] [Related]
52. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis.
Harrison JH; Lazo JS
J Pharmacol Exp Ther; 1987 Dec; 243(3):1185-94. PubMed ID: 2447265
[TBL] [Abstract][Full Text] [Related]
53. IL-12p40(-/-) mice treated with intratracheal bleomycin exhibit decreased pulmonary inflammation and increased fibrosis.
Sakamoto H; Zhao LH; Jain F; Kradin R
Exp Mol Pathol; 2002 Feb; 72(1):1-9. PubMed ID: 11784117
[TBL] [Abstract][Full Text] [Related]
54. Effect of montelukast on basophil releasability in patients with asthma.
Sade K; Kivity S; Fireman E; Schwartz Y; Kivity S
Isr Med Assoc J; 2005 Dec; 7(12):792-5. PubMed ID: 16382702
[TBL] [Abstract][Full Text] [Related]
55. Effect of Feitai on bleomycin-induced pulmonary fibrosis in rats.
Gong LK; Li XH; Wang H; Zhang L; Chen FP; Cai Y; Qi XM; Liu LL; Liu YZ; Wu XF; Huang CG; Ren J
J Ethnopharmacol; 2005 Jan; 96(3):537-44. PubMed ID: 15619575
[TBL] [Abstract][Full Text] [Related]
56. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
Al-Amran FG; Hadi NR; Hashim AM
Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
[TBL] [Abstract][Full Text] [Related]
57. Effect of leukotriene receptor antagonists on lung fibrosis in rats.
Shaker OG; Sourour DA
J Appl Toxicol; 2011 Oct; 31(7):678-84. PubMed ID: 21381050
[TBL] [Abstract][Full Text] [Related]
58. Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis.
Zhao L; Wang X; Chang Q; Xu J; Huang Y; Guo Q; Zhang S; Wang W; Chen X; Wang J
Eur J Pharmacol; 2010 Feb; 627(1-3):304-12. PubMed ID: 19909737
[TBL] [Abstract][Full Text] [Related]
59. Pathophysiological role of mast cells in collagen-induced arthritis: study with a cysteinyl leukotriene receptor antagonist, montelukast.
Shiota N; Shimoura K; Okunishi H
Eur J Pharmacol; 2006 Oct; 548(1-3):158-66. PubMed ID: 16949072
[TBL] [Abstract][Full Text] [Related]
60. Prior SO2 exposure promotes airway inflammation and subepithelial fibrosis following repeated ovalbumin challenge.
Cai C; Xu J; Zhang M; Chen XD; Li L; Wu J; Lai HW; Zhong NS
Clin Exp Allergy; 2008 Oct; 38(10):1680-7. PubMed ID: 18631350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
